Global Disease-Modifying MS Therapies Market to Reach USD 63.3 Billion by 2036

Driven by Early Intervention and Long-Term Therapy Adherence

Apr. 3, 2026 at 11:03am

Got story updates? Submit your updates here. ›

An extreme close-up, translucent X-ray image revealing the intricate structures and neural pathways of a human brain, conceptually representing the complex neurological mechanisms underlying multiple sclerosis.Cutting-edge X-ray imaging technology provides a glimpse into the delicate neural networks affected by multiple sclerosis, informing the development of advanced therapies to manage this complex neurological condition.Newark Today

The global disease-modifying MS therapies market is poised for sustained growth, projected to expand from USD 31,915.8 million in 2026 to USD 63,372.5 million by 2036, registering a CAGR of 7.1% over the forecast period. Growth is being driven by a structural shift toward long-term disease modification, earlier treatment initiation, and sustained therapy usage in multiple sclerosis (MS) management.

Why it matters

The market reflects a transition from episodic care to continuous immune modulation, with therapies prescribed over extended durations to reduce relapse frequency and delay disability progression. Improved diagnostic capabilities and broader neurologist access are expanding the treated patient pool, while real-world evidence and long-term outcomes are increasingly influencing treatment decisions and reimbursement frameworks.

The details

The market is gaining traction as healthcare systems prioritize early diagnosis and sustained treatment to manage disease progression effectively. Disease-modifying therapies (DMTs) are increasingly prescribed soon after diagnosis, extending treatment duration and lifetime patient value. Advancements in MS pathophysiology understanding have expanded therapeutic options, including oral agents, injectables, and monoclonal antibodies. Treatment selection is guided by disease activity, safety profiles, and monitoring requirements rather than simple substitution, reinforcing long-term therapy continuity.

  • The global disease-modifying MS therapies market is projected to expand from USD 31,915.8 million in 2026 to USD 63,372.5 million by 2036.
  • The market is expected to register a CAGR of 7.1% over the forecast period from 2026 to 2036.

The players

Biogen

A leading player in the disease-modifying MS therapies market, focusing on innovative therapies, global access, and strengthening clinical evidence to support long-term disease control.

Roche

A key competitor in the market, investing in efficacy, safety, and alignment with evolving treatment protocols to maintain its position in the disease-modifying MS therapies space.

Novartis

A major player in the disease-modifying MS therapies market, leveraging its expertise in targeted immunomodulatory therapies to address the growing demand for long-term disease management.

Sanofi

A prominent pharmaceutical company competing in the disease-modifying MS therapies market, focusing on expanding access and strengthening its portfolio to meet the evolving needs of MS patients.

Merck KGaA

A key player in the disease-modifying MS therapies market, investing in innovative solutions and collaborating with healthcare providers to improve long-term outcomes for MS patients.

Got photos? Submit your photos here. ›

What’s next

The market presents strong opportunities for sustained growth and improved patient outcomes worldwide as healthcare systems continue to prioritize early diagnosis and long-term therapy adherence in multiple sclerosis management.

The takeaway

The global disease-modifying MS therapies market is poised for significant expansion, driven by the growing emphasis on early intervention, continuous disease management, and the development of innovative therapies that can effectively address the long-term needs of MS patients. This shift in the treatment paradigm is expected to drive market growth and improve patient outcomes in the coming years.